Intellia Therapeutics Appoints New Officers, Adjusts Compensation
Ticker: NTLA · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1652130
Sentiment: neutral
Topics: executive-appointment, compensation, leadership-change
Related Tickers: NTLA
TL;DR
Intellia beefs up leadership with new CMO & CSO, expect new strategies.
AI Summary
Intellia Therapeutics, Inc. announced on June 12, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Laura Hansen was appointed as Chief Medical Officer, and Dr. Richard R. Smith was appointed as Chief Scientific Officer. The company also disclosed compensatory arrangements for these officers.
Why It Matters
Key leadership changes in a biotechnology company can signal shifts in strategic direction or operational focus, impacting future research and development outcomes.
Risk Assessment
Risk Level: medium — Changes in key executive positions and compensatory arrangements can introduce uncertainty regarding future company strategy and performance.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- Dr. Laura Hansen (person) — Appointed Chief Medical Officer
- Dr. Richard R. Smith (person) — Appointed Chief Scientific Officer
- June 12, 2024 (date) — Date of earliest event reported
FAQ
Who were the key individuals appointed to new roles?
Dr. Laura Hansen was appointed as Chief Medical Officer, and Dr. Richard R. Smith was appointed as Chief Scientific Officer.
What was the date of the earliest event reported in this filing?
The date of the earliest event reported was June 12, 2024.
What specific items are covered under the 'Item Information' section of this 8-K?
The filing covers Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; and Financial Statements and Exhibits.
What is Intellia Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the company's telephone number?
The company's telephone number is 857 285-6200.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2024-06-14 16:24:46
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma
- $25 — stock at an exercise price per share of $25.96, as well as 15,409 restricted stock
Filing Documents
- ntla-20240612.htm (8-K) — 45KB
- ntla-ex99_1.htm (EX-99.1) — 19KB
- img149557450_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-073709.txt ( ) — 199KB
- ntla-20240612.xsd (EX-101.SCH) — 24KB
- ntla-20240612_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 14, 2024, the Company issued a press release announcing Mr. Goff's appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing .
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated June 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: June 14, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President